Iveco Group N.V. to present its 2025 First Quarter Results on 15th May 2025Turin, 28th April 2025. Iveco Group N.V. (EXM: IVG) confirmed today that its financial results for the First Quarter of 2025 will be presented on Thursday, 15th May 2025.
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date
ESET announces major integration with Splunk SIEMSAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- ESET, a global leader in cybersecurity solutions, today announced a new major integration of its ESET Endpoint Management Platform (ESET PROTECT) with Splunk, a leading security information and event management (SIEM) platform.
AirNet Announces Termination of Deposit AgreementBEIJING, April 28, 2025 (GLOBE NEWSWIRE) -- AirNet Technology Inc. ("AirNet" or the "Company") (Nasdaq: ANTE), today announced that it will terminate the amended and restated Deposit Agreement dated March 29, 2019, among the Company, JPMorgan Chase Bank N.A. (the “Depositary”), and the holders of American depositary shares (the “ADSs”) from time to time, effective May 30, 2025.
Copenhagen Infrastructure Partners to partially divest Coalburn 1Coalburn 1 is a 500MW construction-stage battery project, which is set to become the biggest of its kind in Europe
Synaptics Unveils First Veros™ Wi-Fi 7 Family Tailored for the IoTWi-Fi, Bluetooth, and Zigbee/Thread combo SoCs support high peak speed and low latency for gaming, AR/VR, entertainment, security, and automotive applications.
ONWARD Medical Announces Release of 2024 Annual ReportEINDHOVEN, the Netherlands, April 28, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces that its Annual Report for the fiscal year ended December 31, 2024 has been filed with the Dutch Authority for the Financial Markets (AFM).
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) –
F.R.I.D.A.Y Planned Maintenance System Receives ClassNK Approval, Advancing Maritime DigitalizationHybrid Cloud and On-Premise ERP Solution Enhances Compliance and Operational Efficiency for Vessel Management
The Rock & Roll Hall of Fame Foundation Unveils Electrifying Class of 2025 Inductees2025 Induction Ceremony Set for Saturday, November 8 in Los Angeles, California and Airing Live on Disney+
Studies Explore How New Treatments, Metabolic Health and Weight Loss Shape Sexual Wellness for Men and WomenLAS VEGAS, April 27, 2025 (GLOBE NEWSWIRE) -- Exciting new research unveiled at the American Urological Association (AUA) Annual Meeting in Las Vegas highlights the evolving landscape of sexual health and wellness for both men and women.
Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood TestBOSTON, April 27, 2025 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared the company’s scientific presentation from the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25 to 30, 2025, in Chicago, Illinois.
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell EngagerWOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, and Celltrion, a leading biopharmaceutical company, today unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2025, in the New Drugs on the Horizon session.
Studies Link Lifestyle, Exercise and Yoga to Improved Urologic Health and Cancer OutcomesLAS VEGAS, April 27, 2025 (GLOBE NEWSWIRE) -- Abstracts being presented at this year's American Urological Association (AUA) Annual Meeting in Las Vegas highlight the powerful role of healthy lifestyle choices in urologic health and cancer management.
Studies Showcase Women’s and Children’s Bladder Health—From Early Symptoms to Innovative TreatmentsLAS VEGAS, April 27, 2025 (GLOBE NEWSWIRE) -- Abstracts presented at this year's American Urological Association (AUA) Annual Meeting in Las Vegas highlight advances in women’s and pediatric urology.
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European UnionSTAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025.
Risk Strategies acquires GMC Advisors, LLCTexas-based commercial lines agency adds to construction, manufacturing, and energy industry expertise
Dr. Tamara Moodie LLC Launches Three New Autism-Focused Publications to Support Empathy, Awareness, and InclusivityMiami, FL, April 27, 2025 (GLOBE NEWSWIRE) -- In a significant step toward advancing autism awareness and fostering inclusive understanding, Dr. Tamara Moodie LLC announces the publication of three insightful works: Walking In My Shoes, Through My Eyes, I Am Still Like You… Autism Through My Point of View, and Empowering Autism Journal. Authored by Dr. Tamara Moodie, these books serve as valuable resources for families, educators, and communities navigating the diverse realities of autism. They provide thoughtful perspectives and practical tools designed to deepen understanding of Autism Spectrum Disorder (ASD) and promote the value of neurodiversity in our communities.
CraveU AI: Launches New AI Girlfriend for Realistic Virtual CompanionshipNEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Cozyai LLC proudly announces the launch of CraveU AI, a new AI girlfriend designed for realistic virtual companionship.
Studies Uncover Hidden Urologic Risks—How Water, Chemicals and Everyday Exposures Impact Urinary HealthLAS VEGAS, April 26, 2025 (GLOBE NEWSWIRE) -- Groundbreaking research presented at the American Urological Association (AUA) Annual Meeting in Las Vegas is shining a spotlight on the hidden environmental factors influencing urinary health.
RAINN Statement on the Passing of Virginia GiuffreWashington, D.C., April 26, 2025 (GLOBE NEWSWIRE) -- Today, RAINN, the nation’s largest anti-sexual violence organization, isssued the following statement upon the news that Virginia Giuffre, who bravely brought forth allegations of sexual abuse against Jeffrey Epstein and his associates, passed away:
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French AuthoritiesSaint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in La Reunion and Mayotte. Valneva has been responding to the French government’s call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through a major chikungunya outbreak with ~ 40,000 confirmed cases since the beginning of 20252.
Studies Unveil Groundbreaking Advances in Prostate Cancer: From AI-Driven Detection to Non-Invasive TestingLAS VEGAS, April 26, 2025 (GLOBE NEWSWIRE) -- Abstracts presented at this year's American Urological Association (AUA) Annual Meeting in Las Vegas will spotlight a series of innovative research studies poised to transform prostate cancer care.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of The BancorpFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Bancorp To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of TFI InternationalFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In TFI To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Open LendingFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Open Lending To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ready CapitalFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ready Capital To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciencesFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Maravai LifeSciences To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of NET PowerFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In NET Power To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Manhattan AssociatesFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Manhattan Associates To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of e.l.f. BeautyFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In e.l.f. Beauty To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Lab USAFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Lab To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of EverusFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Everus To Contact Him Directly To Discuss Their Options
Studies Show Breakthroughs in Male Contraception, Including First Male Contraceptive HydrogelLAS VEGAS, April 26, 2025 (GLOBE NEWSWIRE) -- Groundbreaking research presented at the American Urological Association (AUA) Annual Meeting in Las Vegas is ushering in a new era for men’s reproductive health.
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace MedicalFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Treace Medical To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BigBear.aiFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BigBear.ai To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AppLovinFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AppLovin To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana BiotechnologyFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sana To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Perpetua Resources Corp.Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Perpetua To Contact Him Directly To Discuss Their Options
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ViatrisFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Viatris To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bakkt HoldingsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bakkt To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultra CleanFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultra Clean To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SkyworksFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skyworks To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ActiniumFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fluence EnergyFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fluence To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Solaris EnergyFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Solaris To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of enCoreFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In enCore To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GeronFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Geron To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SoundHound AIFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In SoundHound AI To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ZynexFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of IbottaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ibotta To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel TherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Canopy GrowthFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Canopy Growth To Contact Him Directly To Discuss Their Options
798 Art District and Beijing International Film Festival Jointly Launch “Art Lights the Screen” – A Cultural Feast of Film and ArtBEIJING, April 26, 2025 (GLOBE NEWSWIRE) -- The 798 Art District and the 15th Beijing International Film Festival have officially launched the "Art Lights the Screen" series, running through May 5. Spanning 520,000 m² of 798·751 Community, the event blends technology, art, and film through six thematic units, exhibitions, and flea markets, offering an immersive cultural experience.
GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual MeetingPASADENA, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform that fights cancer by activating the patient’s immune system against the breadth of the patient’s own tumor antigens, is presenting compelling preclinical data on GEN-1013, an Interleukin-12 (IL-12) immunotherapy, at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25th – 30th, in Chicago, IL.
ATKORE ALERT: Bragar Eagel & Squire, P.C. is Investigating Atkore Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmNEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Atkore Inc. (
NYSE:ATKR) on behalf of long-term stockholders following a class action complaint that was filed against Atkore on February 21, 2025 with a Class Period from August 2, 2022 to February 3, 2025. Our investigation concerns whether the board of directors of Atkore have breached their fiduciary duties to the company.
17 Education & Technology Group Inc. Files Its Annual Report on Form 20-FBEIJING, April 25, 2025 (GLOBE NEWSWIRE) -- 17 Education & Technology Group Inc. (
NASDAQ: YQ) (“17EdTech” or the “Company”), a leading education technology company in China, today announced that it filed its annual report on Form 20-F, including its audited financial statements, for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission (the “SEC”) on April 25, 2025. The annual report can be accessed on the Company’s investor relations website at https://ir.17zuoye.com as well as on the SEC’s website at http://www.sec.gov.
